The spotlight might fall more often on the controversial area of embryonic stem cell research when stem cell research is discussed, but that does not mean other areas of stem cell research seize to exist.
Kevin Dalby, Austin, Texas-established professor of chemical biology and medicinal chemistry at the College of Pharmacy, Department of Oncology at The University of Texas at Austin, serves as director of the Targeted Therapeutics Program. He is studying the mechanisms of cancer cell signaling to develop targeted therapeutics. Dr. Dalby’s efforts were recognized by the Cancer Prevention and Research Institute of Texas (CPRIT) and the National Institutes of Health, granting him nearly $5 million to support his research. Dalby has an interest in how cancer stem cells impact cancer drug discovery.
Adult stem cell research has lead to remarkable advancements, while RNA-induced pluripotent stem cell research has recently surfaced as an innovative area of study. Here, Dalby discusses recent progress in some areas of stem cell research.
Comments
Post a Comment